Related Experiment Video
Updated: Apr 13, 2026
An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 29, 2010
Characterization of immunotoxins active against ovarian cancer cell lines
Abstract:
The purpose of the present study was to develop immunotoxins directed against human ovarian carcinoma cells. Four monoclonal antibodies (260F9, 454C11, 280D11, and 245E7) were chosen because they were found to bind to various ovarian carcinoma cell lines. These antibodies were covalently linked to either Pseudomonas exotoxin (PE) or ricin A chain (RTA), and the conjugates were tested against five ovarian cancer cell lines (OVCAR-2, -3, -4, -5; A1847). The ability of the immunotoxins to inhibit both protein synthesis and colony formation was evaluated. Qualitatively similar results were obtained for both types of assays. Usually, PE conjugates were more toxic than their corresponding RTA conjugates. 454C11-PE was very toxic for all ovarian carcinoma lines, whereas 454C11-RTA had low activity. Both 260F9-PE and 260F9-RTA were active in all OVCAR cell lines but not in A1847 cells. 280D11-PE was toxic for OVCAR-4; otherwise, 280D11-PE and RTA conjugates of both 280D11 and 245E7 had little activity. Specificity of immunotoxin action was shown by competition by excess antibody, nontoxicity in nontarget cells, and inactivity of an irrelevant immunotoxin. To investigate the basis of antibody-dependent differences in activity of the various immunotoxins, antibody uptake was studied in OVCAR-2 cells, and the results indicate that antibody internalization is one important factor in the activity of immunotoxins.
Insights
Researchers developed targeted immunotoxins for ovarian cancer, linking antibodies to Pseudomonas exotoxin (PE) or ricin A chain (RTA). PE conjugates generally showed higher toxicity against ovarian carcinoma cells, with antibody internalization influencing efficacy.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Ovarian carcinoma remains a significant health challenge, necessitating novel therapeutic strategies.
- Immunotoxins offer a targeted approach to cancer therapy by selectively delivering cytotoxic agents to tumor cells.
Purpose of the Study:
- To develop and evaluate immunotoxins targeting human ovarian carcinoma cells.
- To assess the efficacy of conjugates formed between monoclonal antibodies and cytotoxic payloads like Pseudomonas exotoxin (PE) and ricin A chain (RTA).
Main Methods:
- Covalent linkage of four monoclonal antibodies (260F9, 454C11, 280D11, 245E7) to PE or RTA.
- Testing immunotoxin activity against five human ovarian cancer cell lines (OVCAR-2, -3, -4, -5; A1847) by measuring inhibition of protein synthesis and colony formation.
- Investigating antibody uptake in OVCAR-2 cells to understand the basis of immunotoxin activity.
Main Results:
- Pseudomonas exotoxin (PE) conjugates were generally more toxic than ricin A chain (RTA) conjugates.
- The 454C11-PE immunotoxin demonstrated high toxicity against all tested ovarian carcinoma lines.
- Antibody internalization was identified as a key factor influencing immunotoxin efficacy.
Conclusions:
- Immunotoxins targeting ovarian carcinoma cells can be effectively developed using monoclonal antibodies conjugated to PE or RTA.
- The choice of antibody and cytotoxic payload significantly impacts immunotoxin activity.
- Antibody internalization is a critical determinant of immunotoxin potency, highlighting its importance in therapeutic design.
